Targeted Therapies and their Impact on Melanoma

Steven O’Day, MD

Video Categories: Targeted Therapies

Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.
March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

October 16, 2015

Anti-CTLA4 vs. Anti-PD-1

Dr. Sanjiv Agarwala examines the benefits of anti-PD-1 therapy vs. anti-CTLA4 therapy and how these therapies may be used on their own and in combination with each other in the future.